GlassScriptPhysician profile
Mark D Wittry
NPI 1497721088
$4,541.82
in general payments reported to CMS, 2019-2025
29 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Nuclear Medicine provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $46.37 · 2021: $17.63 · 2022: $571 · 2023: $588 · 2024: $2,446 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018 · Travel and Lodging: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.48 |
| Travel and Lodging | $1,304.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $1,753.73 | 2024 | Illuccix |
| Edwards Lifesciences Corporation | $718.92 | 2022-2024 | Sapien 3 Ultra Resilia |
| Heartflow, INC. | $256.96 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $221.19 | 2023-2024 | Pylarify |
| Astrazeneca Pharmaceuticals LP | $190.92 | 2022-2024 | Imfinzi, Tagrisso, Wainua |
| Blue Earth Diagnostics | $183.85 | 2019-2025 | Posluma |
| Pfizer INC. | $167.88 | 2019-2024 | |
| Emd Serono, INC. | $148.96 | 2019-2025 | Bavencio |
| Ge Healthcare | $136.97 | 2021-2024 | |
| Advanced Accelerator Applications | $125.11 | 2019 | |
| Medtronic USA, INC. | $122.12 | 2019 | |
| Merck Sharp & Dohme LLC | $101.21 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $84.82 | 2020-2023 | Tukysa, Padcev |
| Novartis Pharmaceuticals Corporation | $43.91 | 2022-2025 | |
| United Imaging Healthcare North America, INC. | $40.97 | 2025 | N/A |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $25.95 | 2019-2023 | Imbruvica |
| Exelixis INC. | $24.56 | 2025 | Cabometyx |
| Abbvie INC. | $19.70 | 2019 | |
| Eisai INC. | $19.28 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.89 | 2019 | |
| Kyowa Kirin, INC. | $18.09 | 2023 | Poteligeo |
| Glaxosmithkline, LLC. | $17.86 | 2020 | |
| Aveo Pharmaceuticals, INC. | $16.11 | 2024 | |
| Taiho Oncology, INC. | $15.60 | 2024 | |
| Genzyme Corporation | $15.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.63 | 2024 | Libtayo |
| Cardinal Health 414 LLC | $13.16 | 2019 | |
| Amgen INC. | $13.15 | 2023 | Lumakras |
| Siemens Medical Solutions USA, INC. | $12.82 | 2023 | Biograph Horizon-3r |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wittry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.